Literature DB >> 18955446

Role of age and health in treatment recommendations for older adults with breast cancer: the perspective of oncologists and primary care providers.

Arti Hurria1, F Lennie Wong, Doojduen Villaluna, Smita Bhatia, Cathie T Chung, Joanne Mortimer, Sara Hurvitz, Arash Naeim.   

Abstract

PURPOSE: To determine the impact of age and health status on adjuvant treatment recommendations for older patients with breast cancer from the perspective of medical oncologists and primary care physicians with geriatric expertise. PATIENTS AND METHODS: One hundred fifty-one oncologists and 158 primary care physicians with geriatric expertise participated in an online survey. The survey described hypothetical patients of varying ages (70, 75, 80, and 85 years) and health status (good, average, and poor) who had node-positive, hormone receptor-positive, human epidermal growth factor receptor 2 (HER-2)/neu-negative; and hormone receptor-negative, HER-2/neu-positive breast cancers. The effects of patient age and health status on the survey participants' adjuvant treatment recommendations were examined using generalized estimation equation methods.
RESULTS: The majority of both oncologists and primary care physicians recommended some form of adjuvant therapy for patients of all ages (70, 75, 80, and 85 years) and health status. Both oncologists and primary care providers were less likely to recommend adjuvant treatment as a patient's age increased or health status declined (P < .0001). There were no significant differences in treatment recommendations among primary care physicians and oncologists for patients with hormone receptor-negative, HER-2/neu-positive tumors (P = .54). However, primary care providers were more likely than oncologists to recommend no adjuvant treatment for patients age 75 years or older with hormone receptor-positive, HER-2/neu-negative tumors (P < .01).
CONCLUSION: Age and health status influence oncologists' and primary care providers' adjuvant treatment recommendations. Evidence-based guidelines for breast cancer treatment in older adults taking into account age and health status are needed.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18955446      PMCID: PMC2651077          DOI: 10.1200/JCO.2008.17.6891

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  21 in total

Review 1.  Assessing the risk of breast cancer.

Authors:  K Armstrong; A Eisen; B Weber
Journal:  N Engl J Med       Date:  2000-02-24       Impact factor: 91.245

2.  Predictors of immediate and 6-month outcomes in hospitalized elderly patients. The importance of functional status.

Authors:  P Narain; L Z Rubenstein; G D Wieland; B Rosbrook; L S Strome; F Pietruszka; J E Morley
Journal:  J Am Geriatr Soc       Date:  1988-09       Impact factor: 5.562

3.  The effect of age on treatment choice and survival in elderly breast cancer patients.

Authors:  L Bergman; G Dekker; F E van Leeuwen; S J Huisman; F S van Dam; J A van Dongen
Journal:  Cancer       Date:  1991-05-01       Impact factor: 6.860

4.  Participation of patients 65 years of age or older in cancer clinical trials.

Authors:  Joy H Lewis; Meredith L Kilgore; Dana P Goldman; Edward L Trimble; Richard Kaplan; Michael J Montello; Michael G Housman; José J Escarce
Journal:  J Clin Oncol       Date:  2003-04-01       Impact factor: 44.544

5.  The effect of age and comorbidity in the treatment of elderly women with nonmetastatic breast cancer.

Authors:  C J Newschaffer; L Penberthy; C E Desch; S M Retchin; M Whittemore
Journal:  Arch Intern Med       Date:  1996-01-08

6.  Breast cancer treatment in older women: impact of the patient-physician interaction.

Authors:  Rose C Maly; Barbara Leake; Rebecca A Silliman
Journal:  J Am Geriatr Soc       Date:  2004-07       Impact factor: 5.562

7.  Breast cancer risk assessment and management in primary care: provider attitudes, practices, and barriers.

Authors:  Susan A Sabatino; Ellen P McCarthy; Russell S Phillips; Risa B Burns
Journal:  Cancer Detect Prev       Date:  2007-11-26

8.  Value of functional status as a predictor of mortality: results of a prospective study.

Authors:  D B Reuben; L V Rubenstein; S H Hirsch; R D Hays
Journal:  Am J Med       Date:  1992-12       Impact factor: 4.965

9.  Cancer treatment and age: patient perspectives.

Authors:  P A Newcomb; P P Carbone
Journal:  J Natl Cancer Inst       Date:  1993-10-06       Impact factor: 13.506

10.  The relationship among physicians' specialty, perceptions of the risks and benefits of adjuvant tamoxifen therapy, and its recommendation in older patients with breast cancer.

Authors:  Karim Malek; Aliza K Fink; Soe Soe Thwin; Jerry Gurwitz; Patricia A Ganz; Rebecca A Silliman
Journal:  Med Care       Date:  2004-07       Impact factor: 2.983

View more
  35 in total

1.  How do oncologists make decisions about chemotherapy for their older patients with cancer? A survey of Australian oncologists.

Authors:  E B Moth; B E Kiely; V Naganathan; A Martin; P Blinman
Journal:  Support Care Cancer       Date:  2017-08-03       Impact factor: 3.603

2.  Predictors of chemotherapy dose reduction at first cycle in patients age 65 years and older with solid tumors.

Authors:  Ajeet Gajra; Heidi D Klepin; Tao Feng; William P Tew; Supriya G Mohile; Cynthia Owusu; Cary P Gross; Stuart M Lichtman; Tanya M Wildes; Andrew E Chapman; Efrat Dotan; Vani Katheria; Laura Zavala; Chie Akiba; Arti Hurria
Journal:  J Geriatr Oncol       Date:  2015-02-07       Impact factor: 3.599

Review 3.  Systemic therapies for metastatic renal cell carcinoma in older adults.

Authors:  Sumanta K Pal; Ari Vanderwalde; Arti Hurria; Robert A Figlin
Journal:  Drugs Aging       Date:  2011-08-01       Impact factor: 3.923

4.  Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study.

Authors:  Arti Hurria; Kayo Togawa; Supriya G Mohile; Cynthia Owusu; Heidi D Klepin; Cary P Gross; Stuart M Lichtman; Ajeet Gajra; Smita Bhatia; Vani Katheria; Shira Klapper; Kurt Hansen; Rupal Ramani; Mark Lachs; F Lennie Wong; William P Tew
Journal:  J Clin Oncol       Date:  2011-08-01       Impact factor: 44.544

5.  The role of age on dose-limiting toxicities in phase I dose-escalation trials.

Authors:  A Schwandt; P J Harris; S Hunsberger; A Deleporte; G L Smith; D Vulih; B D Anderson; S P Ivy
Journal:  Clin Cancer Res       Date:  2014-07-15       Impact factor: 12.531

6.  Race and age disparities in receipt of sentinel lymph node biopsy for early-stage breast cancer.

Authors:  Katherine E Reeder-Hayes; John Bainbridge; Anne Marie Meyer; Keith D Amos; Bryan J Weiner; Paul A Godley; William R Carpenter
Journal:  Breast Cancer Res Treat       Date:  2011-02-22       Impact factor: 4.872

7.  Oncologists' recommendations for adjuvant therapy in hormone receptor-positive breast cancer patients of varying age and health status.

Authors:  Arash Naeim; F Lennie Wong; Sumanta K Pal; Arti Hurria
Journal:  Clin Breast Cancer       Date:  2010-04       Impact factor: 3.225

8.  Predictors of Unplanned Hospitalizations in Patients With Nonmetastatic Lung Cancer During Chemotherapy.

Authors:  Kristen L Fessele; Matthew J Hayat; Robert L Atkins
Journal:  Oncol Nurs Forum       Date:  2017-09-01       Impact factor: 2.172

9.  Factors Associated With Unplanned Hospitalizations Among Patients With Nonmetastatic Colorectal Cancers Intended for Treatment in the Ambulatory Setting.

Authors:  Kristen L Fessele; Matthew J Hayat; Deborah K Mayer; Robert L Atkins
Journal:  Nurs Res       Date:  2016 Jan-Feb       Impact factor: 2.381

10.  Endocrine therapy initiation from 2001 to 2008 varies by age at breast cancer diagnosis and tumor size.

Authors:  Erin J Aiello Bowles; Diana S M Buist; Jessica Chubak; Onchee Yu; Jeanene Johnson; Janet Chestnut; Denise M Boudreau
Journal:  J Oncol Pract       Date:  2012-02-21       Impact factor: 3.840

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.